Anticancer Therapies – Products

Avacta Group plc has announced that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully.

RemeGen Co., Ltd announced the latest clinical research results on disitamab vedotin at this year's American Society of Clinical Oncology Annual Meeting.

As a global leader in the recombinant technology, Sino Biological provides a diverse array of recombinant proteins, antibodies, and ELISA kits to facilitate research and development of cancer treatments that focus on c-Kit and other RTKs (EGFR, VEGFR, PDGFR, c-Met, TrkB, FGFR, and more).

OncoHost has announced that it will give a poster presentation demonstrating the accuracy of its PROphet® biomarker model at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023, in Chicago, Illinois.

uBriGene, a cell & gene therapy contract development and manufacturing organization, is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc.

AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.

Active cell therapy drugs represent the latest in cancer treatment. Of these, chimeric antigen receptor (CAR) cell modalities are considered the most successful.

CAR-T cell therapy has emerged as one of the most promising novel treatments in the fight against cancer.

Certis Oncology Solutions has announced that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting.

Cantargia has announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab, in pancreatic cancer patients.